Suprachoroidal CLS-TA Alone or in Combination With Intravitreal Aflibercept for DME

2016-10-26 05:53:21 | BioPortfolio


To demonstrate the safety and tolerability of suprachoroidal CLS-TA alone or in combination with intravitreal aflibercept in subjects with diabetic macular edema associated with diabetes mellitus.


The purpose of this trial is to evaluate the safety and preliminary efficacy of suprachoroidal (SC) CLS-TA in subjects with DME associated with diabetes mellitus.

CLS-TA, triamcinolone acetonide injectable suspension, is a sterile, preservative-free, aqueous suspension formulated for administration into the eye. The drug product is terminally sterilized and is intended for single use. CLS-TA is supplied as a 40 mg/mL sterile suspension in a 2 mL/13 mm TopLyo single use vial with a rubber stopper and an aluminum seal.

This is a Phase 1/2, multicenter, open-label study in subjects with DME associated with diabetes mellitus. Subjects will be screened and if eligible, will be assigned to a study arm at the Baseline Visit. Following the Baseline Visit, subjects will participate in six monthly follow-up visits for safety and efficacy assessments and to determine whether additional therapy is needed based upon established criteria.

Subjects will be assigned to one of two treatment arms in the study based upon prior treatment for DME in the study eye. Those subjects who have never received treatment in the study eye for DME or whose DME treatment in the study was more than 1 year prior to the screening date, at the PI's discretion, will be enrolled into the TX Naive study arm. Those subjects who have received treatment for DME in the study eye within the last 12 months, will be enrolled into the Previous TX study arm.

Treatment in the TX Naive arm will consist of one unilateral injections of IVT aflibercept in combination with one unilateral injection of SC CLS-TA in the same eye.

Treatment in the Previous TX arm of the study will consist of one unilateral injection of SC CLS-TA.

Approximately 20 subjects will be assigned in a 1:1 ratio where approximately 10 subjects will be enrolled into the TX Naive arm and approximately 10 subjects will be enrolled into the Previous TX arm.

Study Design

Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment


Diabetic Macular Edema


SC CLS-TA, IVT Aflibercept


Not yet recruiting


Greater Houston Retina Research

Results (where available)

View Results


Published on BioPortfolio: 2016-10-26T05:53:21-0400

Clinical Trials [1556 Associated Clinical Trials listed on BioPortfolio]

Assessment of Biomarker Profile in Diabetic Macular Edema With Intravitreal Aflibercept Injection

To assess the biomarker profile in diabetic macular edema patients in response to intravitreal aflibercept injection. Patients with diabetic macular edema who meet study requirements will ...

The Effect of Bevacizumab and Ziv-aflibercept in Diabetic Macular Edema

In this double clinical trial 132 patient with the history of DME (Diabetic Macular Edema) to receive intravitreous bevacizumab at a dose of 1.25mg (44 patient) , ziv-aflibercept at dose o...

Suprachoroidal Injection of CLS-TA Alone or With Aflibercept in Subjects With Diabetic Macular Edema

This study is designed to demonstrate the safety and tolerability of suprachoroidal CLS-TA alone or in combination with intravitreal aflibercept in subjects with diabetic macular edema ass...

A Dose Ranging Study of OPT-302 With Aflibercept for Persistent Diabetic Macular Edema

A two part, multi-center study consisting of a Phase 1b open label, sequential dose escalation followed by a Phase 2a randomized, double-masked, dose expansion evaluating OPT-302 in combin...

Suprachoroidal CLS-TA With Intravitreal Aflibercept Versus Aflibercept Alone in Subject With Diabetic Macular Edema

The purpose of this trial is to evaluate the safety and efficacy of suprachoroidal CLS-TA used with intravitreal aflibercept in subjects with DME.

PubMed Articles [2314 Associated PubMed Articles listed on BioPortfolio]

Intravitreal Ziv-Aflibercept for Diabetic Macular Edema: 48-Week Outcomes.

To study the safety and efficacy of intravitreal injections of ziv-aflibercept (IVI-ZA) (Zaltrap; Sanofi-Aventis and Regeneron Pharmaceuticals, Tarrytown, NY) during a period of 48 weeks in patients w...

Aflibercept in the treatment of diabetic macular edema: a review and consensus paper.

To reach a consensus, among experts, on the role of aflibercept in diabetic macular edema (DME) through literature review.

Evaluating the Relationship Between Visual Acuity and Utilities in Patients With Diabetic Macular Edema Enrolled in Intravitreal Aflibercept Studies.

The purpose of this study was to explore the relationship between visual acuity and utility (health-related quality of life) in diabetic macular edema (DME) using intravitreal aflibercept data.


The aim of this study was to investigate the changes in plasma vascular endothelial growth factor (VEGF) level depending on the severity of diabetic retinopathy (DR) or diabetic macular edema (DME) an...

Diabetic macular edema, innovative technologies and economic impact: New opportunities for the Lombardy Region healthcare system?

Diabetic macular edema (DME) is a leading cause of vision loss and blindness. The aim of this study was to evaluate the economic benefits of introducing additional alternative technologies (Dexamethas...

Medical and Biotech [MESH] Definitions

Fluid accumulation in the outer layer of the MACULA LUTEA that results from intraocular or systemic insults. It may develop in a diffuse pattern where the macula appears thickened or it may acquire the characteristic petaloid appearance referred to as cystoid macular edema. Although macular edema may be associated with various underlying conditions, it is most commonly seen following intraocular surgery, venous occlusive disease, DIABETIC RETINOPATHY, and posterior segment inflammatory disease. (From Survey of Ophthalmology 2004; 49(5) 470-90)

Specialized ophthalmic technique used in the surgical repair and or treatment of disorders that include retinal tears or detachment; MACULAR HOLES; hereditary retinal disease; AIDS-related retinal infections; ocular tumors; MACULAR DEGENERATION; DIABETIC RETINOPATHY; and UVEITIS.

A form of MACULAR DEGENERATION also known as dry macular degeneration marked by occurrence of a well-defined progressive lesion or atrophy in the central part of the RETINA called the MACULA LUTEA. It is distinguishable from WET MACULAR DEGENERATION in that the latter involves neovascular exudates.

Disease of the RETINA as a complication of DIABETES MELLITUS. It is characterized by the progressive microvascular complications, such as ANEURYSM, interretinal EDEMA, and intraocular PATHOLOGIC NEOVASCULARIZATION.

Vision considered to be inferior to normal vision as represented by accepted standards of acuity, field of vision, or motility. Low vision generally refers to visual disorders that are caused by diseases that cannot be corrected by refraction (e.g., MACULAR DEGENERATION; RETINITIS PIGMENTOSA; DIABETIC RETINOPATHY, etc.).

More From BioPortfolio on "Suprachoroidal CLS-TA Alone or in Combination With Intravitreal Aflibercept for DME"

Quick Search


Relevant Topics

Diabetes is a lifelong condition that causes a person's blood sugar level to become too high. The two main types of diabetes are: type 1 diabetes type 2 diabetes In the UK, diabetes affects approximately 2.9 million people. There are a...

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...

Searches Linking to this Trial